Issue of shares, PDMR Dealing and TVR

March 4, 2021
RNS Number : 2460R
Renalytix AI PLC
04 March 2021


Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")


Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights


New York, 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Company's Employee Share Purchase Plan ("the ESPP"), new 17,652 ordinary shares of £0.0025 each in the capital of the Company ("the Ordinary Shares") have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares ("ADSs") by employees who participated in the ESPP.  Further details in relation to the ESPP were contained in the Company's announcement of 2 September 2020.


O. James Sterling, Chief Financial Officer, participated in the plan and acquired 4,596 ordinary shares (2,298 ADSs) at £4.50 per share ($12.563 per ADS).


The purchase of ADSs by certain employees of the Company who are treated as affiliates under U.S. securities laws (including O. James Sterling, Chief Financial Officer) will be settled once certain additional U.S. securities law requirements have been complied with. 

An application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 17,652 new Ordinary Shares to trading on AIM will become effective on, or around, 9 March 2021 ("Admission").

Total voting rights

Following Admission, the Company will have 72,047,286 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,047,286.


For further information, please contact:


Renalytix AI plc

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams

Walbrook PR Limited

Tel: 020 7933 8780 or


Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303



About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.




About RenalytixAI

RenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visit


Notification of dealings in shares by PDMRs of the Company:



Details of PDMR / PDMR Associate



O. James Sterling


Position / status

Chief Financial Officer


Initial notification /



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument

Acquisition of Ordinary Shares to be converted to American Depositary Shares


Nature of the transaction

Acquisition of shares


Price(s) and volume(s)

Price: £4.50 

Volume: 4,596 shares



Aggregated information

Aggregated volume







Date of the transaction

4 March 2021


Place of the transaction

Outside a trading venue


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.